Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review

Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials

(2015) François Raffi et al.   AIDS

Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy

(2015) Nathan Ford et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Brief Report

(2015) Sharon Walmsley et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Dolutegravir – a review of the pharmacology, efficacy, and safety in the treatment of HIV

(2015) Christopher Kandel et al.   Drug Design Development and Therapy

Will drug resistance against dolutegravir in initial therapy ever occur?

(2015) Mark A. Wainberg et al.   Frontiers in Pharmacology

Dolutegravir: Clinical and Laboratory Safety in Integrase Inhibitor–Naive Patients

(2014) L. Curtis et al.   HIV CLINICAL TRIALS

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

(2014) Bonaventura Clotet et al.   LANCET

Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy

(2013) Zara Shubber et al.   AIDS

Dolutegravir in antiretroviral-naive adults with HIV-1

(2013) Hans-Jürgen Stellbrink et al.   AIDS

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

(2013) Pedro Cahn et al.   LANCET

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

(2013) Francois Raffi et al.   LANCET

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

(2013) Sharon L. Walmsley et al.   NEW ENGLAND JOURNAL OF MEDICINE

World Health Organization Guideline Development: An Evaluation

(2013) David Sinclair et al.   PLoS One

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

(2011) Jan van Lunzen et al.   LANCET INFECTIOUS DISEASES

GRADE guidelines: A new series of articles in the Journal of Clinical Epidemiology

(2010) Gordon H. Guyatt et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE